| Source: New Wave Holdings Corp.
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
TORONTO, May 17, 2020 (GLOBE NEWSWIRE) — NEW WAVE HOLDINGS CORP. (the “Company” or “New Wave Holdings“) (CSE: SPOR) (FWB: 0XM2), (OTC:TRMND), is pleased to announce through it’s investment in Anahit Therapeutics Ltd. (“Anahit”), it has entered into a manufacturing agreement with Kirkman®, a FDA and GMP certified manufacturer to launch two proprietary functional mushroom products for the North American market.
Kirkman is a leading manufacturer of nutritional supplements for individuals with dietary sensitivities and restrictions. The company was founded in 1949, making it one of the oldest supplement companies in its niche.
“Kirkman has established itself as a leader in developing effective nutritional supplements for individuals with special health needs,” said Clayton Fisher. “In collaboration with Kirkman, New Wave is launching a proprietary, five-mushroom blend supplement under our Anahit Therapeutics brand, available in both powder and capsule form.”
The blend will contain reishi, cordyceps, lion’s mane, oyster and shiitake mushrooms, each of which has shown to support overall wellness by supporting a restful sleep with less stress, while also supporting stamina and endurance.
“Functional mushrooms are known to have therapeutic properties and research has shown that certain mushroom products can help strengthen the immune system. The blend of mushrooms in our new Anahit supplement are rich in polyphenols, polysaccharides and beta-glucans, and also have antioxidant properties,” added Clayton Fisher.
Kirkman is a GMP (Good Manufacturing Practice) certified manufacturer, which means that it maintains the highest quality and safety standards for the products it produces as per FDA regulations.
All products produced by Kirkman are also tested using its purity testing protocol for environmental contaminants such as pesticides (insecticides, fungicides, herbicides, biocides), endocrine disruptors and other potentially harmful contaminants.
“Pesticide testing is not common practice in the nutraceutical industry except for when it comes to herbal and botanical products, but Kirkman is committed to raising the bar for purity standards in the industry,” added Clayton Fisher. “This is one of the many reasons that we chose to bring them on as a partner.”
ABOUT NEW WAVE HOLDINGS CORP. and ANAHIT THERAPEUTICS LTD.
New Wave Holdings Corp. (CSE: SPOR, FWB: 0XM2, OTC:TRMND) is an investment issuer focused on the burgeoning psychedelic and esports sectors. In the psychedelic sector New Wave will focus on active psychedelic compounds, functional mushroom product lines, and develop an IP portfolio focusing on psilocybin, LSD, MDMA, and ketamine derived treatments for neuropsychiatric diseases.
Investors interested in connecting with New Wave Holdings can learn more about the company and contact the team at http://newwavecorp.com
Media interested in interviews and more information may contact Brittany Whitmore at email@example.com
FOR FURTHER INFORMATION PLEASE CONTACT:
Interim Chief Executive Officer
New Wave Holdings Corp.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
The securities issued in connection with the Transaction and the Offering have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “1933 Act”), or under any state securities laws, and may not be offered or sold, directly or indirectly, or delivered within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the 1933 Act) absent registration or an applicable exemption from the registration requirements. This news release does not constitute an offer to sell or a solicitation to buy such securities in the United States.
All information contained in this news release with respect to Anahit was supplied by Anahit. for inclusion herein, and New Wave’s directors and officers have relied on Anahit for such information.
FORWARD-LOOKING INFORMATION DISCLAIMER
Certain statements contained in this news release may constitute forward‐looking information, including but not limited to, expansion of operations. Forward‐looking information is often, but not always, identified by the use of words such as “anticipate”, “plan”, “estimate”, “expect”, “may”, “will”, “intend”, “should”, and similar expressions. Forward‐looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward‐looking information. The Company’s actual results could differ materially from those anticipated in this forward‐looking information as a result of competitive factors and competition for investment opportunities, challenges relating to operations in international markets, transaction execution risk, changes to the Company’s strategic growth plans, and other factors, many of which are beyond the control of the Company. The Company believes that the expectations reflected in the forward‐looking information are reasonable based on current expectations and potential investment pipeline, but no assurance can be given that these expectations will prove to be correct and such forward‐looking information should not be unduly relied upon. Any forward‐looking information contained in this news release represents the Company’s expectations as of the date hereof, and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward‐looking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.